Send comments and news tips to [email protected]. Cite this: Edited by Shrabasti Bhattacharya. Intensive Bevacizumab Boosts Vision in Macular Degeneration - Medscape - June 19, 2025.

By the end of follow-up, we expected that osimertinib plus bevacizumab could better reduce the risk of intracranial progression and prolong the progression-free survival compared with osimertinib ...

Zentiva provides health and wellbeing for all generations. We are a European company developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 30 ...

ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment ...

ISELIN, N.J., JUNE 10 2025 — Outlook Therapeutics, Inc. (Nasdaq: OTLK), today announced the Scottish Medicines Consortium (SMC) approval of LYTENAVA™ (bevacizumab gamma) for the treatment of wet ...

PRAGUE, June 16, 2025 /PRNewswire/ -- Zentiva today announced the acquisition of five heritage brands from Aboca that will widen access to well-known natural treatments across Europe; due to take ...

BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC), following GMP certifications in Brazil ...

Sanofi is in the final stages of selling its European generics business, Zentiva, to private equity firm Advent International. The companies have signed a share purchase agreement valued at €1.9 ...